We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$163M
AUM Growth
-$69.7M
Cap. Flow
-$60M
Cap. Flow %
-36.95%
Top 10 Hldgs %
62.79%
Holding
55
New
8
Increased
9
Reduced
9
Closed
21

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$6.42M
2
TERN
Terns Pharmaceuticals
TERN
+$4.99M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.79M
4
CBAY
Cymabay Therapeutics
CBAY
+$3.86M
5
KROS icon
Keros Therapeutics
KROS
+$3.74M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$17.8M
2
RLMD icon
Relmada Therapeutics
RLMD
+$13.5M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$9.84M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$8.45M
5
BLU
BELLUS Health Inc.
BLU
+$7.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
2 Miscellaneous 0.01%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
1
Whitehawk Therapeutics
WHWK
$233M
$19.6M 12.08%
1,849,402
– –
VRDN icon
2
Viridian Therapeutics
VRDN
$2.48B
$11.6M 7.13%
396,500
+33,765
+9% +$778K
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$11.2M 6.92%
217,500
-336,500
-61% -$17.8M
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
$11.2M 6.89%
1,100,000
+749,298
+214% +$4.99M
UTHR icon
5
United Therapeutics
UTHR
$21.3B
$9.18M 5.65%
33,000
+5,500
+20% +$1.39M
SRPT icon
6
Sarepta Therapeutics
SRPT
$2.18B
$8.75M 5.38%
67,500
+26,000
+63% +$3.01M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.58B
$8.26M 5.08%
324,614
– –
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.72M 4.75%
360,500
-203,107
-36% -$4.33M
VTYX
9
DELISTED
Ventyx Biosciences
VTYX
$7.56M 4.65%
290,500
+110,500
+61% +$3.27M
PCVX icon
10
Vaxcyte
PCVX
$8.98B
$6.93M 4.26%
144,500
+59,500
+70% +$2.33M
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$6.36M 3.92%
+1,015,000
New +$3.86M
KURA icon
12
Kura Oncology
KURA
$1.04B
$6.22M 3.83%
501,500
-35,000
-7% -$509K
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$5.57M 3.43%
+38,000
New +$6.42M
BLU
14
DELISTED
BELLUS Health Inc.
BLU
$5.2M 3.2%
632,500
-806,000
-56% -$7.52M
CLDX icon
15
Celldex Therapeutics
CLDX
$3.06B
$5.13M 3.15%
115,000
-152,195
-57% -$5.43M
RCKT icon
16
Rocket Pharmaceuticals
RCKT
$384M
$5.09M 3.13%
+260,000
New +$4.79M
BCAB
17
DELISTED
BIOATLA INC
BCAB
$4.13M 2.54%
10,000
-400
-4% -$166K
ACRS icon
18
Aclaris Therapeutics
ACRS
$795M
$4.02M 2.47%
255,000
+94,165
+59% +$1.51M
KROS icon
19
Keros Therapeutics
KROS
$225M
$3.84M 2.36%
+80,000
New +$3.74M
GHRS icon
20
GH Research
GHRS
$1.97B
$2.36M 1.46%
243,250
– –
ARGX icon
21
argenx
ARGX
$62.3B
$1.93M 1.19%
+5,100
New +$1.91M
ARWR icon
22
Arrowhead Research
ARWR
$9.57B
$1.66M 1.02%
41,029
-46,471
-53% -$1.54M
FULC icon
23
Fulcrum Therapeutics
FULC
$288M
$1.35M 0.83%
185,000
-35,000
-16% -$228K
PMVP icon
24
PMV Pharmaceuticals
PMVP
$78M
$1.34M 0.83%
154,471
-29
-0% -$309
EYPT icon
25
EyePoint Inc
EYPT
$344M
$1.06M 0.65%
303,396
– –
1
2 3

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Acuta Capital Partners held 55 positions worth $163M, down 30% from $232M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners withdrew a net $60M in Q4 2022, closing 21 positions and reducing 9 holdings. Its most notable exit was Relmada Therapeutics, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Acuta Capital Partners opened a new position in Mersana Therapeutics worth $5.57M.

  • Acuta Capital Partners's largest Q4 2022 buy was Mersana Therapeutics: 38,000 shares worth $5.57M.
  • Acuta Capital Partners added most to Terns Pharmaceuticals in Q4 2022, an estimated $4.99M increase.
  • Acuta Capital Partners's biggest Q4 2022 reduction was Apellis Pharmaceuticals, cutting an estimated $17.8M.
  • Acuta Capital Partners fully exited Relmada Therapeutics in Q4 2022, selling an estimated $13.5M.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $163M portfolio in Q4 2022.
  • Acuta Capital Partners opened 8 new positions and closed 21 in Q4 2022.
  • Acuta Capital Partners's portfolio value fell 30% quarter-over-quarter to $163M.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.